Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBD218
- Development stage
- Preclinical
- Lead developer
- Genor Biopharma
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GBD218 is an investigational trispecific T-cell engager developed by Genor Biopharma for the treatment of multiple myeloma. It is designed to simultaneously target CD3 on T cells and two distinct antigens on myeloma cells: B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D). This dual-targeting approach aims to overcome the heterogeneous expression of these markers in myeloma patients and prevent antigen-escape-mediated relapse. The antibody is constructed using a "1+1+1" format with "knob into hole" technology and a silenced IgG1 Fc region. To mitigate the risk of cytokine release syndrome (CRS), GBD218 utilizes a low-affinity anti-CD3 arm while maintaining high-potency binding to BCMA and GPRC5D.
- Other names
- CD3/BCMA/GPRC5D trispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)BCMA (B-cell maturation antigen)GPRC5D
Beyond the preview
Go deeper on GBD218.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBD218.